$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

$lgnd Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000088616322000049 Filed on May 09, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$57.42M	$45.69M	$72.47M
YoY Change	-32.19%	-17.15%	3.55%
Cost Of Revenue	$12.36M	$4.699M	$11.98M
YoY Change	-59.6%	-42.34%	2.08%
Gross Profit	$45.06M	$40.99M	$60.49M
YoY Change	-16.69%	-12.78%	3.84%
Gross Profit Margin	78.47%	89.72%	83.46%
Selling, General & Admin	$14.59M	$18.18M	$17.74M
YoY Change	-0.86%	44.06%	-41.04%
% of Gross Profit	32.37%	44.35%	29.32%
Research & Development	$19.12M	$20.31M	$18.24M
YoY Change	19.84%	13.58%	-16.77%
% of Gross Profit	42.43%	49.54%	30.16%
Depreciation & Amortization	$13.27M	$13.66M	$13.17M
YoY Change	5.46%	8.67%	0.53%
% of Gross Profit	29.44%	33.31%	21.77%
Operating Expenses	$45.53M	$20.31M	$47.75M
YoY Change	185.38%	13.58%	-25.56%
Operating Profit	-$469.0K	-$9.306M	$12.73M
YoY Change	-101.03%	-297.37%	-315.83%
Interest Expense	-$2.049M	$789.0K	-$16.42M
YoY Change	-141.96%	-86.47%	183.52%
% of Operating Profit			-128.91%
Other Income/Expense, Net	$82.00K	-$10.83M	-$3.344M
YoY Change	-100.66%	-1132.79%	63.12%
Pretax Income	-$636.0K	-$20.14M	-$7.026M
YoY Change	-101.91%	-449.41%	-308.49%
Income Tax	$259.0K	-$4.755M	-$1.610M
% Of Pretax Income
Net Earnings	-$895.0K	-$15.39M	-$5.416M
YoY Change	-102.91%	-184.97%	-194.01%
Net Earnings / Revenue	-1.56%	-33.67%	-7.47%
Basic Earnings Per Share	-$0.05	-$0.91
Diluted Earnings Per Share	-$53.06K	-$0.91	-$323.6K
COMMON SHARES
Basic Shares Outstanding	16.86M shares	16.82M shares	16.71M shares
Diluted Shares Outstanding	17.06M shares	16.82M shares	16.73M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$147.9M	$204.0M	$341.1M
YoY Change	-50.99%	-39.86%	-17.05%
Cash & Equivalents	$5.280M	$14.99M	$19.52M
Short-Term Investments	$142.7M	$189.0M	$321.6M
Other Short-Term Assets	$7.804M	$4.656M	$4.671M
YoY Change	24.47%	-18.43%	22.21%
Inventory	$24.77M	$25.61M	$27.33M
Prepaid Expenses
Receivables	$62.31M	$41.80M	$85.45M
Other Receivables	$964.0K	$0.00	$6.193M
Total Short-Term Assets	$243.8M	$276.1M	$464.8M
YoY Change	-40.67%	-36.89%	-7.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$70.70M	$24.58M	$20.51M
YoY Change	301.05%	45.5%	42.1%
Goodwill		$181.2M	$181.2M
YoY Change		-4.89%	-4.46%
Intangibles		$539.7M	$551.0M
YoY Change		-7.55%	-7.44%
Long-Term Investments
YoY Change
Other Assets	$41.97M	$6.442M	$2.741M
YoY Change	1384.09%	111.01%	-35.76%
Total Long-Term Assets	$832.5M	$829.1M	$832.8M
YoY Change	-1.52%	-3.33%	-3.35%
TOTAL ASSETS
Total Short-Term Assets	$243.8M	$276.1M	$464.8M
Total Long-Term Assets	$832.5M	$829.1M	$832.8M
Total Assets	$1.076B	$1.105B	$1.298B
YoY Change	-14.33%	-14.67%	-4.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.15M	$6.972M	$8.403M
YoY Change	10.88%	-26.37%	122.07%
Accrued Expenses	$17.05M	$15.88M	$17.58M
YoY Change	68.71%	31.11%	-5.13%
Deferred Revenue		$10.50M	$11.00M
YoY Change		-58.17%	-62.64%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$115.0M	$52.00K	$46.00K
YoY Change	255508.89%	-99.04%	-99.3%
Total Short-Term Liabilities	$167.9M	$42.58M	$41.67M
YoY Change	219.74%	-55.56%	-58.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$176.5M	$320.7M
YoY Change	-100.0%	-49.89%	-27.49%
Other Long-Term Liabilities	$63.40M	$29.19M	$30.98M
YoY Change	126.38%	1.62%	0.36%
Total Long-Term Liabilities	$63.40M	$29.19M	$30.98M
YoY Change	126.38%	1.62%	0.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$167.9M	$42.58M	$41.67M
Total Long-Term Liabilities	$63.40M	$29.19M	$30.98M
Total Liabilities	$273.9M	$312.0M	$476.4M
YoY Change	-41.69%	-43.2%	-27.01%
SHAREHOLDERS EQUITY
Retained Earnings		$468.8M	$449.1M
YoY Change		14.33%	14.58%
Common Stock		$17.00K	$17.00K
YoY Change		0.0%	6.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$802.4M	$793.2M	$821.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.076B	$1.105B	$1.298B
YoY Change	-14.33%	-14.67%	-4.75%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$895.0K	-$15.39M	-$5.416M
YoY Change	-102.91%	-184.97%	-194.01%
Depreciation, Depletion And Amortization	$13.27M	$13.66M	$13.17M
YoY Change	5.46%	8.67%	0.53%
Cash From Operating Activities	$11.88M	$52.01M	$27.64M
YoY Change	-41.58%	383.64%	4507.0%
INVESTING ACTIVITIES
Capital Expenditures	-$6.588M	$4.875M	-$2.195M
YoY Change	37.42%	43.21%	-51.22%
Acquisitions
YoY Change
Other Investing Activities	$44.44M	$0.00	-$33.52M
YoY Change	84.04%	-100.0%	-91.13%
Cash From Investing Activities	$37.85M	$113.9M	-$35.71M
YoY Change	95.58%	74.89%	-90.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$163.4M
YoY Change		50.11%
Cash From Financing Activities	-59.44M	-$170.4M	4.164M
YoY Change	19.03%	85.98%	-115.14%
NET CHANGE
Cash From Operating Activities	11.88M	$52.01M	27.64M
Cash From Investing Activities	37.85M	$113.9M	-35.71M
Cash From Financing Activities	-59.44M	-$170.4M	4.164M
Net Change In Cash	-9.713M	-$4.529M	-3.907M
YoY Change	-5.29%	-71.27%	-99.05%
FREE CASH FLOW
Cash From Operating Activities	$11.88M	$52.01M	$27.64M
Capital Expenditures	-$6.588M	$4.875M	-$2.195M
Free Cash Flow	$18.47M	$47.14M	$29.84M
YoY Change	-26.5%	541.31%	485.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000886163
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-33093
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	LIGAND PHARMACEUTICALS INCORPORATED
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0160744
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5980 Horton Street, Suite 405
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Emeryville
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94608
CY2022Q1	dei	City Area Code CityAreaCode	858
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	550-7500
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	LGND
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16861339	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14993000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19522000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	189006000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	321586000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41797000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	85453000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	25614000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	27326000	USD
CY2022Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	6193000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	4656000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4671000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	276066000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	464751000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	35655000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	34482000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	539707000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	551040000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	181206000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	181206000	USD
CY2022Q1	lgnd	Commercial License Rights CommercialLicenseRights	10121000	USD
CY2021Q4	lgnd	Commercial License Rights CommercialLicenseRights	10110000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24584000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20511000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15783000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16542000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	15620000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	16207000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6442000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2741000	USD
CY2022Q1	us-gaap	Assets Assets	1105184000	USD
CY2021Q4	us-gaap	Assets Assets	1297590000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6972000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8403000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15877000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17579000	USD
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5800000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2022Q1	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	1524000	USD
CY2021Q4	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	2588000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10503000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10996000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1850000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2053000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	52000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	46000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	42578000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41665000	USD
CY2022Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	176540000	USD
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	320717000	USD
CY2022Q1	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	7448000	USD
CY2021Q4	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	8483000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	39480000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	59095000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16758000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15494000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29188000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30977000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	311992000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	476431000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16861000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16861000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16767000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16767000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	325368000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	372969000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1031000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-917000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	468838000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	449090000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	793192000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	821159000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1105184000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1297590000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45693000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55150000	USD
CY2022Q1	us-gaap	Cost Direct Material CostDirectMaterial	4699000	USD
CY2021Q1	us-gaap	Cost Direct Material CostDirectMaterial	8153000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	11813000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	11786000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20307000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17879000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18180000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12617000	USD
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	54999000	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	50435000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9306000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4715000	USD
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-12877000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	13061000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	134000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	296000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	789000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	5831000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2698000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6477000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10834000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1049000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20140000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5764000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4755000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12342000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15385000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	18106000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.10
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16824000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16435000	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.05
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16824000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17248000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15385000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	18106000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-114000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-55000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15499000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18051000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	821159000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-5515000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9044000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-114000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15385000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	793192000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	709525000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20581000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8405000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-55000	USD
CY2021Q1	lgnd	Adjustments To Additional Paid In Capital Warrant And Bond Hedge Unwind Transactions AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions	396000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	-9086000	USD
CY2021Q1	lgnd	Adjustments To Additional Paid In Capital Tax Effect Of Convertible Senior Notes Transactions AdjustmentsToAdditionalPaidInCapitalTaxEffectOfConvertibleSeniorNotesTransactions	2032000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	18106000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	745840000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-15385000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	18106000	USD
CY2022Q1	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	1035000	USD
CY2021Q1	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-1684000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13655000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12565000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-51000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-150000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	326000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4916000	USD
CY2022Q1	lgnd	Amortization Of Commercial License And Other Economic Rights AmortizationOfCommercialLicenseAndOtherEconomicRights	-11000	USD
CY2021Q1	lgnd	Amortization Of Commercial License And Other Economic Rights AmortizationOfCommercialLicenseAndOtherEconomicRights	528000	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1532000	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4840000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9044000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8405000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	16180000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	12408000	USD
CY2022Q1	lgnd	Gain Loss On Short Term Investments GainLossOnShortTermInvestments	-12877000	USD
CY2021Q1	lgnd	Gain Loss On Short Term Investments GainLossOnShortTermInvestments	13090000	USD
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-80000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	238000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-43638000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2411000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-44000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9670000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2708000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	470000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	11993000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1072000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2453000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5695000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	233000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	3768000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	52011000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10754000	USD
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	38190000	USD
CY2021Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	72148000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	132866000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	109407000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	24830000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	31500000	USD
CY2022Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	750000	USD
CY2021Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4875000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3404000	USD
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	240000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	113881000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	65115000	USD
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	163356000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	108822000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3801000	USD
CY2022Q1	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	0	USD
CY2021Q1	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	16855000	USD
CY2022Q1	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2021Q1	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	16459000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	347000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26493000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5862000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5901000	USD
CY2022Q1	lgnd	Payments To Contingent Value Right Holders Financing Activity PaymentsToContingentValueRightHoldersFinancingActivity	1416000	USD
CY2021Q1	lgnd	Payments To Contingent Value Right Holders Financing Activity PaymentsToContingentValueRightHoldersFinancingActivity	0	USD
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-121000	USD
CY2021Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-170421000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-91635000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4529000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15766000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19522000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47963000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14993000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32197000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	359000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3700000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7300000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45693000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55150000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	172435000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	531000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4105000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	168861000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	241000	USD
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	344000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2574000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	87000	USD
CY2022Q1	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	306000	USD
CY2021Q1	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	775000	USD
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-114000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-55000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div>
CY2022Q1	lgnd	Debt Securities Available For Sale And Equity Securities Fvni DebtSecuritiesAvailableForSaleAndEquitySecuritiesFVNI	189006000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	292225000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	842000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2370000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	290697000	USD
CY2021Q4	lgnd	Debt Securities Available For Sale And Equity Securities Fvni DebtSecuritiesAvailableForSaleAndEquitySecuritiesFVNI	321586000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	10095000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	10011000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis	6523000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	6398000	USD
CY2022Q1	us-gaap	Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	16618000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	16409000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	13	position
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2022Q1	lgnd	Covid19 Accounts Receivable Allowance For Credit Loss Period Increase Decrease COVID19AccountsReceivableAllowanceForCreditLossPeriodIncreaseDecrease	-100000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	181206000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	181206000	USD
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	720913000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	732246000	USD
CY2010Q1	lgnd	Number Of Contingent Value Rights Series NumberOfContingentValueRightsSeries	4	contingent_value_right_series
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3620000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6532000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3974000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2046000	USD
CY2022Q1	lgnd	Licensee Accrual Current LicenseeAccrualCurrent	2677000	USD
CY2021Q4	lgnd	Licensee Accrual Current LicenseeAccrualCurrent	630000	USD
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	149000	USD
CY2022Q1	lgnd	Returns Accrual ReturnsAccrual	0	USD
CY2021Q4	lgnd	Returns Accrual ReturnsAccrual	2420000	USD
CY2022Q1	lgnd	Accrued Asset Acquisitions Current AccruedAssetAcquisitionsCurrent	0	USD
CY2021Q4	lgnd	Accrued Asset Acquisitions Current AccruedAssetAcquisitionsCurrent	1000000	USD
CY2022Q1	lgnd	Accrued Subcontractor Expenses Current AccruedSubcontractorExpensesCurrent	1757000	USD
CY2021Q4	lgnd	Accrued Subcontractor Expenses Current AccruedSubcontractorExpensesCurrent	1759000	USD
CY2022Q1	lgnd	Accrued Supplier Expenses Current AccruedSupplierExpensesCurrent	1697000	USD
CY2021Q4	lgnd	Accrued Supplier Expenses Current AccruedSupplierExpensesCurrent	848000	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	394000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	291000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1758000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1904000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15877000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17579000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	9044000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	8405000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.005
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.50
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.63
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M12D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16824000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16435000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16824000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17248000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6001000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4277000	shares
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9306000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4715000	USD
CY2022Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	reporting_unit
CY2021	lgnd	Payments To Unwind Warrants PaymentsToUnwindWarrants	18400000	USD
CY2021	lgnd	Proceeds From Unwinding Convertible Bond Hedges ProceedsFromUnwindingConvertibleBondHedges	18900000	USD
CY2021Q4	lgnd	Number Of Options Under Convertible Bond Hedges NumberOfOptionsUnderConvertibleBondHedges	598021	option
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	500000	USD
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.236
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-2.141
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1500000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	100.59
CY2019Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	500000000	USD
CY2019Q3	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P3Y
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	USD
CY2022Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	248800000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15783000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16542000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	15620000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	16207000	USD
CY2022Q1	lgnd	Lease Right Of Use Asset LeaseRightOfUseAsset	31403000	USD
CY2021Q4	lgnd	Lease Right Of Use Asset LeaseRightOfUseAsset	32749000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1850000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2053000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	52000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	46000	USD
CY2022Q1	lgnd	Lease Liability Current LeaseLiabilityCurrent	1902000	USD
CY2021Q4	lgnd	Lease Liability Current LeaseLiabilityCurrent	2099000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16758000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15494000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	39000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	58000	USD
CY2022Q1	lgnd	Lease Liability LeaseLiability	18699000	USD
CY2021Q4	lgnd	Lease Liability LeaseLiability	17651000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1020000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2712000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2716000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2614000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2700000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2727000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	8074000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	22563000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3864000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	18699000	USD

Files In Submission

Name	View Source	Status
0000886163-22-000049-index-headers.html	Edgar Link	pending
0000886163-22-000049-index.html	Edgar Link	pending
0000886163-22-000049.txt	Edgar Link	pending
0000886163-22-000049-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lgnd-20220331.htm	Edgar Link	pending
lgnd-20220331.xsd	Edgar Link	pending
lgnd-20220331_cal.xml	Edgar Link	unprocessable
lgnd-20220331_def.xml	Edgar Link	unprocessable
lgnd-20220331_g1.jpg	Edgar Link	pending
lgnd-20220331_htm.xml	Edgar Link	completed
lgnd-20220331_lab.xml	Edgar Link	unprocessable
lgnd-20220331_pre.xml	Edgar Link	unprocessable
lgnd_33122exhibit311.htm	Edgar Link	pending
lgnd_33122exhibit312.htm	Edgar Link	pending
lgnd_33122exhibit321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

2022 Q2 Form 10-Q Financial Statement

#000088616322000049 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND LIGAND PHARMACEUTICALS INC Stock $lgnd

2022 Q2 Form 10-Q Financial Statement

#000088616322000049 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd